Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: dasatinib
Trade Name: Sprycel
Date Designated: 11/28/2005
Orphan Designation: Treatment of chronic myelogenous leukemia
Orphan Designation Status: Designated/Approved
Bristol-Myers Squibb Company
3401 Princeton Pike, B-3043C
Lawrence Township, New Jersey 08648
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: dasatinib
Trade Name: Sprycel
Marketing Approval Date: 06/28/2006
Approved Labeled Indication: Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
Exclusivity End Date: 06/28/2013 
Exclusivity Protected Indication* :  
2 Generic Name: dasatinib
Trade Name: Sprycel
Marketing Approval Date: 11/09/2017
Approved Labeled Indication: Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
Exclusivity End Date: 11/09/2024 
Exclusivity Protected Indication* :  Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-